


SANYOU Protein Preparation and Reagent Product All-inclusive Package






Off-the- Shelf Cell Line Products


Diverse Rapid Protein Preparation

Sanyou Bio protein preparation platform, refined over 8 years, has established a eukaryotic rapid protein production platform. This platform offers the flexibility to combine different host cells, expression volumes, protein quantities, purification methods, and QA techniques according to specific requirements. It is adaptable to various scenarios, catering to a diverse customer needs for rapid protein production.




Highly Challenging Protein Products

Sanyou Bio provides services for preparing highly challenging protein products, including G-protein coupled receptors (GPCRs), solute carrier superfamily proteins, protein variants/intermediates, proteins with unique structures, and proteins with special modifications.



Case Studies

GPCRs are a major transmembrane protein family in mammalian genomes. They are found in various organs including the central nervous system, immune system, cardiovascular system, and retina. Their unique seven-transmembrane structure and ligand interactions contribute significantly to signal transduction, molecular transport, and energy utilization. GPCRs play a pivotal role in regulating body functions and maintaining homeostasis.



///////// BIOLOGICAL DRUG R&D · ASK SANYOU BIO

Reference Drug Products

Sanyou Bio can provide experimentally validated biological drug reference standards, including monoclonal reference antibodies, multi-specific reference antibodies, reference antibody-drug conjugates (ADC), and reference Fc fusion proteins. These products are applicable for project development, mechanism research, and functional validation within the field of biopharmaceutical research. They play a vital role in advancing the biopharmaceutical research and development

Product Category

Monoclonal Reference Antibodies

1000+products with all clinical stages

Example:

.

- Atezolizumab (PD-L1)
- Pembrolizumab (PD-1)
- Nivolumab (PD-1)
- Trastuzumab (HER2)
- Talquetamab (GPRC5D)



Multi-specific Reference Antibodies

200+products with 20+ structura design *Example*:

- Blinatumomab (CD3&CD19)
- Glofitamab (CD3&CD20)
- Cadonilimab (PD-1&CTLA4)
- Amivantamab (EGFR&cMet)
- TG-1801 (CD19&CD47)

Reference Antibody-drug Conjugates

50+products with 10+ toxin

Example:

.

- Sacituzumab govitecan (TROP2)
- Trastuzumab deruxtecan (HER2)
- Telisotuzumab vedotin (c-Met)
- Disitamab vedotin (HER2)
- Mirvetuximab soravtansine (FRA)

Reference Fc Fusion Proteins

10+most renovated products

Example:

.

- GLP-1
- SIRPα
- IL2
- 4-1BB
- TGF-β






All products are intended for scientific research purpose only and are not intended for direct human application. They should not be used for medical, therapeutic, or edible purposes.


Core Reagent Products

Product Categories: Diverse Range of Products Empowering Biological Research




Customized Protein Preparation

Sanyou Bio protein preparation platform accommodates a wide range of protein types from diverse sources including proteins with varying complexities. Our platform utilizes five major expression systems to comprehensively cover all classic expression systems. With our extensive purification processes and robust quality control, we are fully equipped to meet our customers' protein customization needs.




Purification Techniques






Gel Filtration

Ion Exchange



Hydrophobic Interaction Chromatography




Affinity Chromatography

Catalog-style Cell Line Products


Sanyou Bio provides off-the-shelf overexpression cell lines, as well as services for pre-designed products and personalized services.

Promotion: 450 USD per cell line. (Limited to 5 cell lines per organization)



/ / / / / / / / BIOLOGICAL DRUG R&D · ASK SANYOU BIO

Sanyou Protein Package at a Glance





The CRS website includes four major categories of products: proteins, antibodies, cell lines, and diagnostics reagents. https://crs.sanyoubio.com/



Global Sites

Sanyou Biopharmaceuticals has successively established office locations in China, Shanghai, USA (Boston, San Diego, Philadelphia), UK, London, and Netherlands, Rotterdam.



USA: yongqiang.li@sanyoubiopharma.com / EU and other countries: chuan.liu@sanyoubiopharma.com CN: qiang.chen@sanyoubio.com TEL: 400-821-0776

Scientific research achievements

Sanyou has facilitated customers in publishing high-impact research articles, contributing to nearly 50 publications, including top-tier journals like Cell, Nature and Science.



Representative examples of published papers

- [01] Hastie K M, Li H, Bedinger D, et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study
 [J]. Science, 2021, 374(6566): 472-478. IF: 47.728
- [02] Hu W, Zhang Y, Fei P, et al. Mechanical activation of spike fosters SARS-CoV-2 viral infection[J]. Cell research, 2021, 31(10): 1047-1060.IF: 25.617
- [03] Yao H, Sun Y, Deng Y Q, et al. Rational development of a human antibody cocktail that deploys multiple functions to confer Pan-SARS-CoVs protection[J]. Cell research, 2021, 31(1): 25-36.**IF: 25.617**
- [04] Yu Y, Li J, Solomon S A, et al. All-printed soft human-machine interface for robotic physicochemical sensing[J]. Science robotics, 2022, 7(67): eabn0495. IF: 23.748
- [05] Yang Y, Peng Y, Lin C, et al. Human ACE2-functionalized gold "virus-trap" nanostructures for accurate capture of SARS-CoV-2 and single-virus SERS detection[J]. Nano-micro letters, 2021, 13: 1-13. **IF: 16.419**
- [06] Torrente-Rodríguez R M, Lukas H, Tu J, et al. SARS-CoV-2 RapidPlex: a graphene-based multiplexed telemedicine platform for rapid and low-cost COVID-19 diagnosis and monitoring[J]. Matter, 2020, 3(6): 1981-1998. **IF: 15.589**
- [07] Jiang H, Li Y, Zhang H, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses[J]. Nature communications, 2020, 11(1): 3581.IF: 14.919
- [08] Wu Y, Cui Z, Huang Y H, et al. Towards a generic prototyping approach for therapeutically-relevant peptides and proteins in a cell-free translation system[J]. Nature Communications, 2022, 13(1): 260. IF: 14.919
- [09] Chi H, Wang L, Liu C, et al. An Engineered IgG-VHH Bispecific Antibody against SARS CoV 2 and Its Variants[J]. Small Methods, 2022, 6(12): 2200932. IF: 14.188
- [10] Yi C, Sun X, Ye J, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies[J]. Cellular & molecular immunology, 2020, 17(6): 621-630. IF: 11.53

THREE CORE TECHNOLOGY PLATFORMS



ST-AL based molecule generation



Integrated drug discovery



COMPREHENSIVE LAYOUT OF FOUR BUSINESS MODELS



PCC integrated service Antibody generation Antibody engineering Pharmacodynamics



IND integrated service Cell line / Process **CPO** Technology transfer

Collaborative R&D



Protein customization Antibody products Protein products Diagnostic materials

MULTIDIMENSIONAL SYSTEMIC SOLUTIONS







Scientific innovation



Sanyou Biopharmaceuticals Co., Ltd. www.sanyoubio.com (2) +86 021 3368 1627

protein@sanyoubio.com / service@sanyoubio.com

● 3F | Bldg. 6 | No. 188 Xinjunhuan Rd. | Minhang District | Shanghai | China | 201114

B7.14-2308EN